Citigroup’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.15M | Sell |
98,000
-90,000
| -48% | -$6.27M | ﹤0.01% | 1804 |
|
|
2025
Q4 | $12.5M | Buy |
188,000
+65,000
| +53% | +$4.2M | 0.01% | 1379 |
|
|
2025
Q3 | $8.28M | Buy |
123,000
+60,000
| +95% | +$4.75M | ﹤0.01% | 1626 |
|
|
2025
Q2 | $5.5M | Sell |
63,000
-290,000
| -82% | -$22.7M | ﹤0.01% | 1811 |
|
|
2025
Q1 | $24.1M | Sell |
353,000
-35,000
| -9% | -$2.86M | 0.01% | 863 |
|
|
2024
Q4 | $30.2M | Buy |
388,000
+81,000
| +26% | +$6M | 0.02% | 740 |
|
|
2024
Q3 | $20.6M | Buy |
307,000
+184,000
| +150% | +$15.1M | 0.01% | 929 |
|
|
2024
Q2 | $13.9M | Buy |
+123,000
| New | +$15.6M | 0.01% | 1078 |
|
|
2024
Q1 | – | Sell |
-125,000
| Closed | -$15.5M | – | 5689 |
|
|
2023
Q4 | $15.5M | Hold |
125,000
| – | – | 0.01% | 993 |
|
|
2023
Q3 | $11.7M | Hold |
125,000
| – | – | 0.01% | 1032 |
|
|
2023
Q2 | $16.1M | Sell |
125,000
-150,000
| -55% | -$18.1M | 0.01% | 923 |
|
|
2023
Q1 | $31.9M | Buy |
275,000
+3,000
| +1% | +$336K | 0.02% | 586 |
|
|
2022
Q4 | $30.8M | Sell |
272,000
-125,000
| -31% | -$13.7M | 0.02% | 593 |
|
|
2022
Q3 | $32M | Buy |
397,000
+347,000
| +694% | +$29.4M | 0.02% | 556 |
|
|
2022
Q2 | $3.73M | Buy |
+50,000
| New | +$4.56M | ﹤0.01% | 1704 |
|
|
2022
Q1 | – | Sell |
-40,000
| Closed | -$5.37M | – | 6379 |
|
|
2021
Q4 | $5.37M | Buy |
+40,000
| New | +$5.75M | ﹤0.01% | 1774 |
|
|
2021
Q1 | – | Sell |
-151,200
| Closed | -$14M | – | 6524 |
|
|
2020
Q4 | $14M | Buy |
151,200
+48,800
| +48% | +$4.36M | 0.01% | 1291 |
|
|
2020
Q3 | $10.6M | Buy |
102,400
+8,000
| +8% | +$836K | 0.01% | 1337 |
|
|
2020
Q2 | $9.57M | Sell |
94,400
-56,400
| -37% | -$5.05M | 0.01% | 1322 |
|
|
2020
Q1 | $10.2M | Buy |
150,800
+3,200
| +2% | +$199K | 0.01% | 1150 |
|
|
2019
Q4 | $8.07M | Buy |
147,600
+114,000
| +339% | +$5.41M | 0.01% | 1653 |
|
|
2019
Q3 | $1.25M | Sell |
33,600
-47,600
| -59% | -$1.85M | ﹤0.01% | 3384 |
|
|
2019
Q2 | $3.04M | Buy |
81,200
+38,400
| +90% | +$1.21M | ﹤0.01% | 2386 |
|
|
2019
Q1 | $1.27M | Buy |
42,800
+26,400
| +161% | +$928K | ﹤0.01% | 3146 |
|
|
2018
Q4 | $491K | Sell |
16,400
-28,400
| -63% | -$901K | ﹤0.01% | 4143 |
|
|
2018
Q3 | $1.6M | Buy |
44,800
+36,800
| +460% | +$1.14M | ﹤0.01% | 2969 |
|
|
2018
Q2 | $190K | Sell |
8,000
-18,000
| -69% | -$382K | ﹤0.01% | 5115 |
|
|
2018
Q1 | $482K | Sell |
26,000
-3,200
| -11% | -$47.3K | ﹤0.01% | 4025 |
|
|
2017
Q4 | $419K | Buy |
29,200
+4,000
| +16% | +$52K | ﹤0.01% | 4293 |
|
|
2017
Q3 | $308K | Buy |
25,200
+12,400
| +97% | +$219K | ﹤0.01% | 4595 |
|
|
2017
Q2 | $234K | Sell |
12,800
-7,600
| -37% | -$140K | ﹤0.01% | 4658 |
|
|
2017
Q1 | $432K | Sell |
20,400
-22,800
| -53% | -$445K | ﹤0.01% | 3998 |
|
|
2016
Q4 | $645K | Buy |
43,200
+16,400
| +61% | +$291K | ﹤0.01% | 4116 |
|
|
2016
Q3 | $587K | Buy |
+26,800
| New | +$596K | ﹤0.01% | 3757 |
|
Other funds holding DXCM
VCM
VPM
Citigroup's DXCM Position: Q1 2026 in Review
Citigroup reduced its DexCom (DXCM) stake by 1.4% in Q1 2026, selling an estimated $830K and leaving 834,087 shares worth $52.4M. The position accounts for 0.02% of the portfolio, ranked #630.
Citigroup first reported a position in DXCM in Q2 2013 and has held it in 52 quarters since. The position peaked at $108M in Q4 2023. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Citigroup held 834,087 shares of DexCom worth $52.4M as of Q1 2026.
- Citigroup sold 11,916 DexCom shares in Q1 2026, an estimated $830K.
- DexCom made up 0.02% of Citigroup's portfolio in Q1 2026, its #630 holding.
- Citigroup first reported a position in DexCom in Q2 2013 and has held it in 52 quarters since.
- Citigroup's DexCom position peaked at $108M in Q4 2023.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.